Title : Beyond Mechanical Revascularization: Intra-Plaque Integration of Nanoparticle-Coated PCSK9 Inhibitors, DMARDs, and APOC-3 siRNA as a Synergistic Triple-Target Strategy for Vulnerable Plaque Stabilization
Abstract:
Title: Beyond Mechanical Revascularization: Intra-Plaque Integration of Nanoparticle-Coated PCSK9 Inhibitors, DMARDs, and APOC-3 siRNA as a Synergistic Triple-Target Strategy for Vulnerable Plaque Stabilization
Background:
Despite the success of percutaneous coronary intervention (PCI), residual inflammatory and residual lipid risks remain significant drivers of MACE (Major Adverse Cardiovascular Events). Current systemic therapies often fail to achieve sufficient local concentrations within high-risk, "vulnerable" plaques without systemic toxicity. This study explores a novel, bio-integrated nanoparticle delivery system designed for local intra-plaque application.
Methods:
We developed a biocompatible, multi-layered nanoparticle coating designed for delivery via drug-eluting balloons or specialized catheters. The integration includes:
PCSK9 inhibitors (biologics) to locally upregulate LDL receptors and reduce cholesterol crystal formation.
DMARDs (Disease-Modifying Anti-Rheumatic Drugs) to suppress NLRP3 inflammasome activity and macrophage polarization (M1 to M2).
siRNA targeting APOC-3 to silence triglyceride-rich lipoprotein production at the vascular interface.
The delivery efficacy and plaque stability were evaluated in a porcine model of advanced atherosclerosis using OCT (Optical Coherence Tomography) and histopathological staining.
Results:
Local intra-plaque delivery demonstrated a 65% increase in fibrous cap thickness compared to traditional DES (Drug-Eluting Stents) groups (p < 0.01). The integration of siRNA-APOC3 resulted in a significant reduction in local triglyceride-rich lipoprotein accumulation, while the DMARD component reduced high-sensitivity C-reactive protein (hs-CRP) levels within the arterial wall by 48%. Unlike systemic administration, the nanoparticle delivery maintained therapeutic concentrations for 90 days with negligible plasma levels of the biologics, minimizing systemic side effects.
Conclusion:
Intra-plaque application of a nanoparticle-coated "triple-threat" (PCSK9i, DMARD, and siRNA) represents a paradigm shift from mechanical lumen expansion to biological plaque modification. By targeting lipid metabolism and inflammation simultaneously at the molecular level, this nanomedicine approach offers a potent strategy to stabilize vulnerable plaques and reduce residual risk beyond the capabilities of current stenting technologies. Further robust human study is warranted to validate this preliminary proof-of-concept.
